Nilesh Gupta, Managing Director, Lupin, said, ''We ended the year on a positive note with growth across all our key markets. We took a one-time impairment on the Gavis acquisition in line with the changed market conditions, in particular with the opioids in the US. We have made meaningfulstrides in our complex generics pipeline, made progress on the Speciality build across US, Europe and Japan and have had strong growth in the Emerging Markets, especially India. Our near-term priorities are resolution of the Warning Letter on Goa and Indore Unit 2, successful commercialization of Solosec in the US and executing on meaningful product launches.''